(Liver Cancer) Efficacy of Nivolumab in Cancer Patients with Impaired Liver Function
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
Anti-PD-1 Antibody Nivolumab in Liver Cancer
- February 27, 2019
- Reading time: 1 minute
Efficacy of the anti-PD-1 antibody nivolumab in patients with advanced hepatocellular carcinoma and impaired liver function
At the ASCO GI 2019 Gastrointestinal Cancers Symposium held in San Francisco, January 17–19, 2019, Dr. Masatoshi Kudo of the Gastroenterology Division, Kinki University Hospital, presented CheckMate 040 Phase 2 clinical trial results for the anti-PD-1 antibody nivolumab in 49 patients with hepatocellular carcinoma and impaired liver function.
The trial administered nivolumab 240 mg every two weeks to patients with hepatocellular carcinoma, continuing until disease progression or intolerable adverse reactions. Primary endpoints included ORR (objective response rate) and DOR (duration of response).
Key results:
- ORR (objective response rate): 10.2%
- DCR (disease control rate): 55.1%
- TTR (time to response): Mean 2.7 months
- DOR (duration of response): Mean 9.9 months
Overall survival (OS):
- Sorafenib-naive patients: OS 9.8 months
- Sorafenib-pretreated patients: OS 7.3 months
Safety: Adverse event rate was 51% (25/49 patients), but the treatment discontinuation rate due to adverse events was only 4.1% (2/49 patients).
Based on these results, continuous nivolumab treatment demonstrated efficacy in patients with advanced hepatocellular carcinoma and impaired liver function, with a low rate of treatment discontinuation due to side effects.
Source: Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. (ASCO GI 2019, Abstract No. 327)
Tags: #LiverCancer
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4